MedPath

Central European Cooperative Oncology Group

🇦🇹Austria
Ownership
-
Established
1999-01-01
Employees
-
Market Cap
-
Website
http://www.cecog.org/

Dose Density FU 75 and FU 90 as Adjuvant Therapy for Early Breast Cancer

Phase 2
Completed
Conditions
Breast Cancer
Interventions
Drug: the FEC75 and 95 regimen
First Posted Date
2006-02-06
Last Posted Date
2012-05-16
Lead Sponsor
Central European Cooperative Oncology Group
Target Recruit Count
50
Registration Number
NCT00286819
Locations
🇦🇹

AKH, Universitätsklinik für Innere Medizin 1, Vienna, Austria

🇭🇺

Onkotherápiás Klinika,, Szeged, Hungary

🇵🇱

Medical University of Gdansk, Dept. of Oncology and Radiotherapy, Gdansk, Poland

and more 2 locations

Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer

Phase 2
Completed
Conditions
Metastatic Colorectal Cancer
Interventions
Drug: Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan
Drug: FOLFOX 6
Drug: FOLFIRI
First Posted Date
2006-02-03
Last Posted Date
2012-05-01
Lead Sponsor
Central European Cooperative Oncology Group
Target Recruit Count
150
Registration Number
NCT00286130
Locations
🇭🇷

University Hospital Rebro, Zagreb, Croatia

🇮🇱

Souraski Medical Center, Tel Aviv, Israel

🇭🇷

University Hospital for Tumors, Zagreb, Croatia

and more 23 locations
© Copyright 2025. All Rights Reserved by MedPath